Northland Capital Markets Starts Biotricity (BTCY) at Outperform, $7 PT

Northland Capital Markets analyst Jason Wittes initiates coverage on Biotricity (OTC: BTCY) with an Outperform rating and a price target of $7.00.

The analyst commented, "We are initiating coverage on BTCY with an Outperform rating and $7 PT. BTCY has disrupted the $1 billion Mobile Cardiac Telemetry (MCT), with improved technology and significantly better economics for the doctors—driving consistent quarterly sequential growth while establishing one of the largest direct network’s of cardiologists. This is a true tech company with a leverageable SaaS like platform and significant expansion opportunities, both in core cardiac testing and beyond."

For an analyst ratings summary and ratings history on Biotricity click here. For more ratings news on Biotricity click here.

Shares of Biotricity closed at $3.15 yesterday.

You May Also Be Interested In

• DA Davidson Starts Everus (ECG) at Buy
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS